Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

Cancer

Volumn 113, Issue 1, 2008, Pages 186-192

  Gilbert, Jill ^a   Cmelak, Anthony ^a   Shyr, Yu ^a   Netterville, James ^a   Burkey, Brian B ^a   Sinard, Robert J ^a   Yarbrough, Wendall G ^a   Chung, Christine H ^a   Aulino, Joseph M ^a   Murphy, Barbara A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Concurrent chemoradiotherapy; Irinotecan; Metastatic. refractory; Squamous cell carcinoma of the head and neck

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 47149084570     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23545     Document Type: Article

References (32)

1. Close LC, Larson DL, Shah JP. Essentials of Head and Neck Oncology. New York, NY: Thieme Medical Publishers Inc.; 1998.
2. Forastiere AA, Metch B, Schuller D, et al. Randomized comparison of cisplatin and 5-fluorouracil versus carboplatin and 5-FU versus methotrexate in advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:1245-1251.
3. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2002;10: 257-263.
4. Shin DM, Glisson BS, Khuri FR, et al. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 1997;19(6 suppl):S19-S37.
5. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002;20:1593-1599.
6. Murphy BA, Cmelak A, Burkey B, et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology. 2001;15:47-52.
7. Murphy BA. New drug therapy for squamous cell carcinoma of the head and neck. Curr Opin Oncol. 1996;8:221-226.
8. Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996;56:789-793.
9. Aoe K, Kiura K, Ueoka H, et al. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res. 2004;24:3893-3897.
10. Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin and cisplatin against human lung tumor xenografts. Jpn J Cancer Res. 1993;84:203-207.
11. Kim HT, Han JY, Lee DH, et al. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer. 2006;107:799-805.
12. Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology. 2004;18:22-25.
13. Sohn JH, Moon YW, Lee CG, et al. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small cell lung cancer. Cancer. 2007;109: 1845-1850.
14. Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol. 1998;16:3858-3865.
15. Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res. 2001;7:68-73.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
17. Gilbert J, Dang T, Cmelak A, et al. Single agent irinotecan for the treatment of metastatic or recurrent squamous carcinoma of the head and neck (SCCHN). Clin Med Oncol. 2007;1:67-71.
18. Chang AA, Van Waes C. Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol. 2005;62:92-102.
19. Allen CT, Ricker JL, Chen Z, et al. Role of activated nuclear factor-kappa B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 2007;29:959-971.
20. Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokines and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2005;27:771-784.
21. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage. 2000;20:214-232.
22. Garattini S. Pharmacokinetics in cancer chemotherapy. Eur J Cancer. 2007;43:271-282.
23. Innocenti F, Undevia SD, Iyer L, et al. Genectic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388.
24. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-3068.
25. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
26. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (Extreme) study [abstract]. Proc Am Soc Clin Oncol. 2007;25:18s. Abstract 6091.
27. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [abstract]. J Clin Oncol. 2004;22 (suppl): 488s. Abstract 5502.
28. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12:600-607.
29. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
30. Prewett M, Hooper A, Bassi R, et al. Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-225 in combination with 5-fluorouracil or irinotecan [abstract]. Proc Am Assoc Cancer Res. 2001;42:287. Abstract 1543.
31. Braun AH, Stark K, Dirsch O, et al. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs. 2005;16:1099-1108.
32. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol. 2007;25: 3930-3935.